AXA/2026/Q1 earnings press release

Document info
Document info
Organization	AXA
Year	2026
Period	Q1
Period label	1Q26
Document type	Earnings press release
Publication date	2026-05-05
Market timing	Pre-market
Language	English
Pages	16
Source	Original URL

This document is AXA's Q1 2026 activity indicators press release, published on May 5, 2026.

1Q26 highlights

Gross written premiums & other revenues +6% vs. 1Q25 to EUR 38.0bn ^{p. 1}
Property & Casualty premiums +4% to EUR 21.5bn ^{p. 1}
- Retail premiums +7% (+4% from price effect, +3% from volumes) ^{p. 1}
- Commercial premiums +3% (equal contributions from price effect and volumes) ^{p. 1}
Life & Health premiums +8% to EUR 16.5bn ^{p. 1}
- Life premiums +8% ^{p. 1}
- Health premiums +8% ^{p. 1}
Life & Health NB CSM +4% ^{p. 1}
Net flows for Life & Health EUR +2.7bn ^{p. 1}
Solvency II ratio was 211% as of March 31, 2026 ^{p. 1}
Solvency II ratio decreased by -4 points vs. January 1, 2026 (post-grandfathering period) ^{p. 1}

Outlook 3

AXA is on track to achieve underlying earnings per share growth for 2026 at the upper end of the 6-8% plan target range ^{p. 1}
AXA will present its new strategic plan for 2027-2029 on September 15, 2026 ^{p. 1}
> "AXA delivered a strong start to the year, with topline growth across all business lines, fully aligned with our organic growth strategy," said Alban de Mailly Nesle, Chief Financial Officer of AXA. "This performance underscores the continued robust expansion of our P&C businesses in both Retail and Commercial, with growth well balanced between pricing and volumes, while Life & Health revenues reflect the continuation of last year's strong momentum." ^{p. 1}
> "In the context of a volatile macro environment, we operate from a position of strength, supported by a robust balance sheet, a Solvency II ratio of 211% and a high-quality investment portfolio. This gives us strong resilience and flexibility. We remain confident in our ability to deliver underlying earnings per share growth for 2026 at the top end of our target range and to sustain growth beyond the current plan." ^{p. 1}
> "I would like to express my gratitude to our colleagues, agents, and partners for their dedication, as well as to our clients for their continued trust in AXA." ^{p. 1}

Press release

The press release was issued on Paris, May 5, 2026 (5:45pm CET) ^{p. 1}
The 1Q26 activity indicators show sustained revenue momentum ^{p. 1}

1Q26 key highlights

Gross written premiums and revenues by business line for 1Q25 and 1Q26. ^{p. 2}
EUR bn	1Q25	1Q26	Change	Change LFL
Gross written premiums and other revenues	37.0	38.0	+3%	+6%
o/w Property & Casualty	21.0	21.5	+2%	+4%
o/w Life & Health	15.5	16.5	+7%	+8%
o/w Asset Management	0.4	n.m.	n.m.	n.m.

Solvency II ratio for FY25, January 1, 2026, and 1Q26. ^{p. 2}
EUR bn	FY25	January 1, 2026	1Q26	Change vs. January 1, 2026
Solvency II ratio (%)	224%	215%	211%	-4pts

Activity indicators

Total gross written premiums & other revenues +6% ^{p. 2}
- Property & Casualty +4% ^{p. 2}
  - Personal lines +7% (driven by higher volumes and favorable price effect) ^{p. 2}
  - Commercial lines +3% (from higher volumes, notably at AXA XL Insurance, and favorable price effect mainly in SME & Mid-market business in Europe and France) ^{p. 2}
  - AXA XL Reinsurance -7% (reflecting discipline in softening market conditions) ^{p. 2}
- Life & Health +8% ^{p. 2}
  - Life premiums +8% (driven by strong sales in Unit-Linked (+16%) and G/A (+9%) across all geographies, and Protection (+4%) from strong sales in Protection with Savings in Hong Kong and Japan) ^{p. 2}
  - Health premiums +8% (driven by favorable price effects across all geographies) ^{p. 2}
Solvency II ratio was 211% as of March 31, 2026 ^{p. 2}
On January 1, 2026, the Solvency II ratio was 215% following the end of the grandfathering period ^{p. 2}
The Solvency II ratio on January 1, 2026, was -10 points lower than December 31, 2025 ^{p. 2}
The Solvency II ratio decreased by -4 points vs. January 1, 2026, due to: ^{p. 2}
- Strong operating return (+7 points), less accrued dividend and annual share buyback for 1Q26 (-6 points) ^{p. 2}
- Unfavorable financial market movements (-4 points), notably from higher inflation expectations and elevated equity and interest rate volatility ^{p. 2}

Property & Casualty

Property & Casualty gross written premiums and revenues by line of business. ^{p. 3}
EUR bn	1Q25	1Q26	Change LFL	1Q26 Price effect (in %)
Gross written premiums and other revenues	21.0	21.5	+4%	+1.9%
o/w Commercial lines	13.2	13.2	+3%	+1.5%
o/w Personal lines	6.4	7.0	+7%	+4.0%
o/w AXA XL Reinsurance	1.4	1.2	-7%	-3.9%

Gross written premiums & other revenues for P&C were +4% to EUR 21.5bn ^{p. 3}
Personal lines grew by 7% to EUR 7.0bn, driven by: ^{p. 3}
- Europe (+7%) from favorable price effects (except UK & Ireland) and higher volumes ^{p. 3}
- France (+8%) with strong volume growth from direct business and proprietary agent networks, combined with favorable price effect ^{p. 3}
- Asia, Africa & EME LATAM (+7%) mainly from higher average premiums in Türkiye and higher volumes in Mexico ^{p. 3}
Commercial lines grew by 3% to EUR 13.2bn, mainly from: ^{p. 3}
- AXA XL Insurance (+2%) from growth in Property and Specialty, partly offset by lower volumes in Casualty; pricing stable vs. 1Q25 ^{p. 3}
- France (+6%) from both favorable price effect and higher volumes ^{p. 3}
- Asia, Africa & EME-LATAM (+10%) mainly from higher average premiums in Türkiye ^{p. 3}
AXA XL Reinsurance decreased by 7% to EUR 1.2bn, reflecting lower volumes and a focus on profitability in a softer market environment, with pricing down -4% ^{p. 3}
Group natural catastrophe experience in 1Q26 was slightly below the prorated annual budget ^{p. 3}
The annual natural catastrophe budget of ca. 4.5 points of combined ratio is maintained ^{p. 3}

Life & Health

Life & Health gross written premiums, PVEP, NB CSM, and NBV. ^{p. 4}
EUR bn	1Q25	1Q25 Updated*	1Q26	Change vs. 1Q25 Updated* LFL
Gross written premiums and other revenues	15.5	—	16.5	+8%
o/w Life	9.8	—	10.5	+8%
o/w Health	5.6	—	5.9	+8%
PVEP	13.7	13.0	13.8	+8%
NB CSM (pre-tax)	0.6	0.6	0.6	+4%
NBV (post-tax)	0.7	0.6	0.6	+1%
NBV margin	4.9%	4.8%	4.4%	-0.3pt

1Q25 PVEP, NB CSM, NBV, and NBV margin have been updated based on FY25 financial and actuarial assumptions for comparability ^{p. 4}
Gross written premiums & other revenues for Life & Health were +8% to EUR 16.5bn ^{p. 4}
Life premiums increased by 8% to EUR 10.5bn, driven by: ^{p. 4}
- Unit-Linked (+16%) from continued positive sales momentum across geographies ^{p. 4}
- G/A Savings (+9%) mainly from successful commercial campaigns in Spain, strong single-premium sales in Japan, good performance of G/A capital-light products in Italy, and positive momentum in Individual Savings in Switzerland ^{p. 4}
- Protection (+4%) primarily from continued success of Protection with G/A savings in Hong-Kong and Protection with Unit-Linked in Japan, as well as Individual Protection with Savings in Switzerland ^{p. 4}
Health premiums increased by 8% to EUR 5.9bn, driven by favorable price effects across all geographies ^{p. 4}
PVEP was +8% to EUR 13.8bn, driven by: ^{p. 4}
- Life (+10%) reflecting strong sales across geographies in both Savings (+14%) and Protection (+6%), partly offset by lower Group Life sales in Switzerland ^{p. 4}
- Health (+4%) mainly due to higher Group business volumes in France, partly offset by Japan ^{p. 4}
NB CSM (pre-tax) increased by 4% to EUR 0.6bn, driven by strong Savings and Protection sales across most geographies, partly offset by unfavorable mix (lower Group Life sales in Switzerland and Health sales in Japan) ^{p. 4}
NBV (post-tax) was +1% to EUR 0.6bn, as NB CSM growth was partly offset by lower sales and a less favorable mix in Joint Ventures in Thailand and China ^{p. 4}
NBV margin decreased by 0.3 points to 4.4% ^{p. 4}
Net flows were EUR +2.7bn, compared to EUR +2.5bn in 1Q25, driven by: ^{p. 4}
- Protection (EUR +1.8bn) mainly in Hong Kong and Switzerland (Individual Life), and Japan (Protection with Unit-Linked product) ^{p. 4}
- Unit-Linked (EUR +0.7bn) primarily in France ^{p. 4}
- G/A Savings (EUR -0.8bn) reflecting inflows in capital-light G/A savings (EUR +0.7bn) more than offset by outflows in traditional G/A Savings (EUR -1.5bn) ^{p. 4}
- Health (EUR +1.0bn) mostly from Germany, France and Japan ^{p. 4}

Ratings

Financial strength and credit ratings from S&P, Moody's, and AM Best. ^{p. 5}
Agency	Date of last review	Insurer financial strength ratings AXA SA	Insurer financial strength ratings AXA's principal insurance subsidiaries	Insurer financial strength ratings Outlook	AXA's credit ratings Senior debt of the Company	AXA's credit ratings Short-term debt of the Company
S&P Global Ratings	March 11, 2026	AA-	AA	Stable	AA-	A-1+
Moody's Investor Service	October 8, 2025	Aa2	Aa2	Stable	Aa3	P-1
AM Best	October 9, 2025	A+ Superior	—	Stable	aa Superior	—

## Glossary

Capital-light G/A products: encompass all products with no guarantees, with guarantees at maturity only or with guarantees equal to or lower than 0%.

Contractual service m argin ('CSM') : a component of the carrying amount of the asset or liability for a group of insurance contracts representing the unearned profit to be recognized as services are provided to policyholders.

Gross written premiums and other revenues: insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business). Other Revenues represent premiums and fees collected on activities other than insurance (i.e. banking, services, and asset management activities).

New business contractual service m argin ('NB CSM'): a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided.

New business value ('NBV'): the value of newly issued contracts during the current year. It consists of the sum of (i) the NB CSM, (ii) the present value of the future profits of Short-Term Business newly issued contracts during the period, carried by Life entities, considering expected renewals, and (iii) the present value of the future profits of pure investment contracts accounted for under IFRS 9, net of (iv) the cost of reinsurance, (v) taxes and (vi) minority interests.

New business value m argin ('NBV Margin'): the ratio of (i) NBV representing the value of newly issued contracts during the current year to (ii) PVEP.

Present value of expected p remiums ('PVEP'): the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term. PVEP is discounted at the reference interest rate and PVEP is Group share.

Scope

France includes insurance activities, banking activities, and holding ^{p. 6}
Europe includes Switzerland (insurance), Germany (insurance and holding), Belgium and Luxemburg (insurance and holding), UK and Ireland (insurance and holding), Spain (insurance and holding), Italy (insurance), Prima (insurance), AXA Health International (insurance), and AXA Life Europe (insurance) ^{p. 6}
AXA XL includes insurance and reinsurance activities and holding ^{p. 6}
Asia, Africa & EME-LATAM includes: ^{p. 6}
- Asia: Japan (insurance and holding), Hong Kong (insurance), Thailand P&C, Indonesia L&S (excl. bancassurance), China P&C, South Korea, and Asia Holdings (fully consolidated); China L&S, Thailand L&S, Philippines L&S and P&C, Indonesia L&S (bancassurance) (consolidated under equity method, contributing to NBV, PVEP, underlying earnings, and net income) ^{p. 6}
- Africa: Egypt (insurance and holding), Morocco (insurance and holding), and Nigeria (insurance and holding) (fully consolidated) ^{p. 6}
- EME-LATAM: Mexico (insurance), Colombia (insurance), Brazil (insurance and holding), and Türkiye (insurance and holding) (fully consolidated); Russia (Reso) (insurance) (consolidated under equity method, contributing to net income) ^{p. 6}
- AXA Mediterranean Holdings ^{p. 6}
Transversal & Other includes AXA Assistance, Credit and Lifestyle Protection (CLP), AXA Liabilities Managers, AXA SA (incl. Group's internal reinsurance activity), and other Central Holdings ^{p. 6}
AXA Investment Managers' disposal to BNP Paribas was completed on July 1, 2025 ^{p. 6}

Exchange rates

Exchange rates for major currencies against the Euro for FY25 and 1Q26. ^{p. 6}
For 1 Euro	FY25	1Q26	1Q25	1Q26
USD	1.17	1.15	1.05	1.17
CHF	0.93	0.93	0.95	0.92
GBP	0.87	0.87	0.84	0.87
JPY	184	183	160	184
HKD	9.14	9.03	8.19	9.14

Glossary

Changes in gross written premiums & other revenues, NBV, PVEP, and NBV Margin are on a comparable basis (constant forex, scope, and methodology) unless otherwise indicated ^{p. 7}
The Solvency II ratio is estimated using AXA's internal model calibrated based on an adverse 1/200 years shock ^{p. 7}
The Solvency II ratio includes a theoretical amount for dividends and share buybacks accrued for the first three months of 2026 ^{p. 7}
This theoretical amount is based on a full-year dividend of EUR 2.32 per share for FY25 and an annual share buyback of EUR 1.25bn announced on February 26, 2026 ^{p. 7}
Annual share buybacks exclude anti-dilutive share buybacks related to disposals and in-force management, and share buybacks to offset dilutive effects from employee share offerings and stock-based compensation ^{p. 7}
Dividends and share buybacks are proposed by the Board and submitted to shareholders for approval ^{p. 7}
The estimate should not be considered an indication of actual dividend and share buyback amounts for 2026 ^{p. 7}
Expected underlying earnings per share ('UEPS') growth for 2026 is a forward-looking statement providing one-off guidance for the last year of the current strategic plan ^{p. 7}
'Commercial lines' refers to P&C Commercial lines excluding AXA XL Reinsurance ^{p. 7}
Price effect is calculated as a percentage of total gross written premiums of the prior year ^{p. 7}
G/A refers to General account ^{p. 7}
Capital instruments and subordinated debt subject to Solvency II transitional measures were grandfathered until January 1, 2026, after which they ceased to qualify as capital under Solvency II ^{p. 7}
Natural catastrophe charges include natural catastrophe losses regardless of event size ^{p. 7}
Combined ratio is a non-GAAP financial measure (Alternative Performance Measure or APM) ^{p. 7}
Life & Health net flows, PVEP, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities ^{p. 7}
Restricted Tier 1 is rated 'A' by Standard & Poor's and 'A3 (hyb)' by Moody's ^{p. 7}
Tier 2 is rated 'A' by Standard & Poor's and 'A (hyb)' by Moody's ^{p. 7}
AXA completed its acquisition of a majority stake in Prima in Italy on November 28, 2025 ^{p. 7}
All comments and changes for activity indicators are on a comparable basis (constant forex, scope, and methodology) ^{p. 7}
Actuarial and financial assumptions for NBV and PVEP are updated semi-annually at half year and full year ^{p. 7}
Financial figures and information in this press release have not been audited or subject to limited review by AXA's statutory auditors ^{p. 7}
AM: AM Best
AMF: Autorité des Marchés Financiers
APM: Alternative Performance Measure
CLP: Credit and Lifestyle Protection
CSM: Contractual Service Margin
DJSI: Dow Jones Sustainability Index
DPF: Discretionary Participation Features
EME: Emerging Markets Europe
ESMA: European Securities and Markets Authority
GAAP: Generally Accepted Accounting Principles
IFRS: International Financial Reporting Standards
LATAM: Latin America
LFL: Like-for-Like
NB CSM: New Business Contractual Service Margin
NBV: New Business Value
OTC QX: Over The Counter QX
PVEP: Present Value of Expected Premiums
SME: Small and Medium-sized Enterprises
SRI: Socially Responsible Investment
UEPS: Underlying Earnings Per Share
UK: United Kingdom
UN: United Nations
UNEP FI: United Nations Environment Programme's Finance Initiative

About the AXA Group

The AXA Group is a worldwide leader in insurance with 156,000 employees serving over 92 million clients in 52 countries ^{p. 8}
In 2025, revenues amounted to EUR 115.5bn and underlying earnings to EUR 8.4bn ^{p. 8}
The AXA ordinary share is listed on compartment A of Euronext Paris under ticker symbol CS (ISN FR 0000120628) ^{p. 8}
AXA's American Depository Share is quoted on the OTC QX platform under ticker symbol AXAHY ^{p. 8}
The AXA Group is included in main international SRI indexes like Dow Jones Sustainability Index (DJSI) and FTSE4GOOD ^{p. 8}
AXA is a founding member of the UN Environment Programme's Finance Initiative (UNEP FI) Principles for Sustainable Insurance and a signatory of the UN Principles for Responsible Investment ^{p. 8}
This press release and regulated information are available on the AXA Group website (axa.com) ^{p. 8}
Certain statements in the press release are forward-looking, including predictions of future events, trends, plans, expectations, or objectives ^{p. 8}
Forward-looking statements are identified by words like 'expects', 'anticipates', 'may', 'plan', or conditional verbs like 'would' and 'could' ^{p. 8}
Statements regarding expected underlying earnings per share ('UEPS') growth for 2026 are forward-looking guidance for the last year of the current strategic plan ^{p. 8}
Forward-looking statements are based on Management's current views and intentions and are subject to change, risks, and uncertainties ^{p. 8}
Undue reliance should not be placed on forward-looking statements due to known and unknown risks outside AXA's control ^{p. 8}
AXA disclaims any obligation to update or revise forward-looking statements, except as required by law ^{p. 8}
The press release refers to non-GAAP financial measures (Alternative Performance Measures or APMs) used by Management ^{p. 8}
These non-GAAP measures generally have no standardized meaning and may not be comparable to those used by other companies ^{p. 8}
Non-GAAP measures should not be considered in isolation from or as a substitute for the Group's consolidated financial statements ^{p. 8}
'Underlying earnings', UEPS, 'underlying return on equity', 'combined ratio', and 'debt gearing' are APMs as defined in ESMA's guidelines and AMF's position statement ^{p. 8}
Reconciliations of APMs to financial statements are provided in the 2025 Universal Registration Document ^{p. 8}
Investor Relations contact: +33.1.40.75.48.42, investor.relations@axa.com ^{p. 8}
Individual Shareholder Relations contact: +33.1.40.75.48.43 ^{p. 8}
Media Relations contact: +33.1.40.75.46.74, ziad.gebran@axa.com, ahlem.girard@axa.com, sylwia.tulak@axa.com ^{p. 8}
Corporate Responsibility strategy information is available at axa.com/en/about-us/strategy-commitments ^{p. 8}
SRI ratings information is available at axa.com/en/investor/sri-ratings-ethical-indexes ^{p. 8}

Appendix 1: Earnings

This section is titled "APPENDIX 1: GROSS WRITTEN PREMIUMS & OTHER REVENUES BY GEOGRAPHY AND BUSINESS LINE" ^{p. 9}.

Earnings by segment for 1Q25 and 1Q26. ^{p. 9}
EUR m	1Q25 Published	1Q25 Adjusted	1Q26	Change vs. 1Q25 Adjusted	Change LFL	1Q26	Change LFL	1Q26	Change LFL
France i,ii,iii	8,440	7,923	8,393	+6%	+5%	3,355	+6%	5,012	+4%
Europe iii	15,289	15,608	16,905	+8%	+6%	9,328	+4%	7,577	+9%
AXA XL	6,984	6,984	6,488	-7%	0%	6,459	0%	29	-1%
Asia, Africa & EME-LATAM	5,286	5,286	5,403	+2%	+11%	1,719	+8%	3,684	+13%
Transversal ii	525	723	764	+6%	+6%	601	+8%	163	-2%
AXA Investment Managers	443	443	—	n.m.	n.m.	—	—	—	—
Total i	36,967	36,967	37,953	+3%	+6%	21,462	+4%	16,464	+8%

Banking revenues were EUR 26m in 1Q26 and EUR 25m in 1Q25 ^{p. 9}.
Portfolio of lifestyle and income protection (CLP) premiums were reallocated from France to Transversal ^{p. 9}.
- In 1Q25, these reallocated premiums amounted to EUR 198m, with EUR 68m in P&C and EUR 130m in Life & Health ^{p. 9}.
- In 1Q26, these reallocated premiums amounted to EUR 201m, with EUR 68m in P&C and EUR 132m in Life & Health ^{p. 9}.
International protection and health premiums previously reported under AXA France are now reported under AXA Health International, which is part of Europe ^{p. 9}.
- In 1Q25, these premiums were EUR 319m, with EUR 104m in Life and EUR 215m in Health ^{p. 9}.
- In 1Q26, these premiums were EUR 336m, with EUR 103m in Life and EUR 233m in Health ^{p. 9}.

Earnings by business line and region for 1Q26. ^{p. 10}
EUR m	Commercial lines	Commercial lines Change	Personal lines	Personal lines Change	Personal lines	Personal lines Change	Personal lines	Personal lines Change	AXA XL Reinsurance	AXA XL Reinsurance Change	1Q26	Change
France	2,061	+6%	766	+10%	528	+4%	1,294	+8%	—	—	3,355	+6%
Europe	4,388	+1%	3,370	+10%	1,570	+2%	4,940	+7%	—	—	9,328	+4%
AXA XL	5,215	+2%	—	—	—	—	—	—	1,244	-7%	6,459	0%
Asia, Africa & EME-LATAM	952	+10%	577	+8%	190	+2%	767	+7%	—	—	1,719	+8%
Transversal	601	+8%	—	—	—	—	—	—	—	—	601	+8%
Total	13,217	+3%	4,712	+9%	2,288	+2%	7,001	+7%	1,244	-7%	21,462	+4%

Changes are presented on a comparable basis, meaning constant forex, scope, and methodology ^{p. 10}.
This section includes "Interest Rates (5Y) For the Discounting of P&C Claims Reserves" ^{p. 10}.

Currency breakdown of earnings for FY25 and 1Q26. ^{p. 10}
—	FY25	1Q26
EUR	2.6%	2.7%
USD	4.2%	4.0%
JPY	1.0%	1.6%
GBP	4.3%	4.2%
CHF	0.2%	0.2%
HKD	3.2%	2.8%

GIE_AXA_Internal

GIE_AXA_Secret GIE_AXA_Internal GIE_AXA_Secret

P&C price effect by country and business line for 1Q26. ^{p. 11}
P&C: Price effect by country and business line 1Q26 (in %)	Commercial lines	Personal lines
France	+3.5%	+2.6%
Europe	+3.0%	+4.2%
Switzerland	+4.0%	+5.1%
Germany	+2.5%	+4.2%
Belgium & Luxembourg	+2.2%	+2.4%
UK & Ireland	+0.5%	-0.9%

P&C price effect for Spain, Italy, and AXA XL for 1Q26. ^{p. 11}
Spain	+5.7%	+6.0%
AXA XL ii	-0.2%	—	-3.9%

P&C price effect for Asia, Africa & EME-LATAM, and Total for 1Q26. ^{p. 11}
Asia, Africa & EME-LATAM	+0.4%	+5.6%
Total	+1.5%	+4.0%	-3.9%

This section is blank ^{p. 12}.

Earnings by segment and type for 1Q26. ^{p. 12}
EUR m	1Q26	Change	1Q26	Change	1Q26	Change	1Q26	Change	1Q26	Change
France	5,012	+4%	996	+3%	1,325	+1%	1,437	+7%	1,253	+4%
Europe	7,577	+9%	1,986	0%	1,263	+16%	1,044	+24%	3,283	+8%
AXA XL	29	-1%	15	+1%	14	-2%	—	—	—	—
Asia, Africa & EME-LATAM	3,684	+13%	1,764	+10%	319	+27%	224	+35%	1,377	+10%
Transversal	163	-2%	132	-1%	—	—	—	—	31	-5%
Total	16,464	+8%	4,893	+4%	2,922	+9%	2,705	+16%	5,944	+8%
o/w short-term iii	5,436	+6%	1,183	+1%	—	—	—	—	4,253	+7%

PVEP, NB CSM, NBV, and NBV margin for 1Q25, 1H25, and 9M25 have been updated based on FY25 actuarial and financial assumptions ^{p. 13}.

Updated earnings figures by segment for 1Q25. ^{p. 13}
1Q25 Updated figures	1Q25 Updated figures	1Q25 Updated figures	1Q25 Updated figures	1Q25 Updated figures	1Q25 Updated figures	1Q25 Updated figures	1Q25 Updated figures	1Q25 Updated figures	1Q25 Updated figures	1Q25 Updated figures	1Q25 Updated figures	1Q25 Updated figures
—	—	—	—	—	—	—	—	—	Total i	Total i	Total i	Total i
EUR m	PVEP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)	PVEP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)	PVEP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)
France ii,iii	3,026	94	103	3.4%	1,565	—	44	2.8%	4,591	94	147	3.2%
Europe iii	2,982	183	161	5.4%	1,627	74	66	4.0%	4,609	257	227	4.9%
Asia, Africa & EME-LATAM	3,128	178	185	5.9%	612	67	61	9.9%	3,740	245	246	6.6%
Transversal ii	63	5	3	5.2%	—	—	—	—	63	5	3	5.2%
Total	9,199	460	452	4.9%	3,805	141	170	4.5%	13,003	601	623	4.8%

Updated earnings figures by segment for 1H25. ^{p. 13}
1H25 Updated figures	1H25 Updated figures	1H25 Updated figures	1H25 Updated figures
—	—	—	—	—	—	—	—	—	Total i	Total i	Total i	Total i
EUR m	PVEP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)	PVEP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)	PVEP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)
France ii,iii	6,969	204	245	3.5%	3,261	—	82	2.5%	10,229	204	327	3.2%
Europe iii	5,585	328	271	4.8%	2,109	83	76	3.6%	7,694	410	347	4.5%
Asia, Africa & EME-LATAM	6,228	389	380	6.1%	1,120	140	120	10.7%	7,347	529	500	6.8%
Transversal ii	153	12	8	5.2%	—	—	—	—	153	12	8	5.2%
Total	18,934	934	904	4.8%	6,490	223	278	4.3%	25,424	1,156	1,182	4.6%

Updated earnings figures by segment for 9M25. ^{p. 13}
9M25 Updated figures	9M25 Updated figures	9M25 Updated figures	9M25 Updated figures	9M25 Updated figures	9M25 Updated figures	9M25 Updated figures	9M25 Updated figures	9M25 Updated figures	9M25 Updated figures	9M25 Updated figures	9M25 Updated figures	9M25 Updated figures
—	Life	Life	Life	Life	—	—	—	—	Total i	Total i	Total i	Total i
EUR m	PVEP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)	PVEP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)	PVEP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)
France ii,iii	9,911	277	344	3.5%	4,788	—	116	2.4%	14,698	277	459	3.1%
Europe iii	7,900	450	365	4.6%	3,215	114	104	3.2%	11,115	564	469	4.2%
Asia, Africa & EME-LATAM	9,408	600	592	6.3%	1,502	199	167	11.1%	10,910	799	759	7.0%
Transversal ii	230	18	12	5.2%	—	—	—	—	230	18	12	5.2%
Total	27,448	1,345	1,312	4.8%	9,505	313	387	4.1%	36,953	1,659	1,698	4.6%

Caption: New Business Value (NBV) breakdown for Life and Health. ^{p. 13}

New Business Value (NBV) breakdown for Life and Health. ^{p. 13}
EUR m	Life	Health	Total
NB CSM (pre-tax)	460	141	601
Other NBV(pre-tax)	133	82	215
Tax	-141	-53	-194
Total NBV	452	170	623

New Business Value (NBV) breakdown for Life and Health. ^{p. 13}
EUR m	Life	Health	Total
NB CSM (pre-tax)	934	223	1,156
Other NBV(pre-tax)	258	144	402
Tax	-288	-89	-377
Total NBV	904	278	1,182

EUR m	Life	Health	Total
NB CSM (pre-tax)	1,345	313	1,659
Other NBV(pre-tax)	384	198	583
Tax	-418	-125	-543
Total NBV	1,312	387	1,698

The change is compared to 1Q25 updated figures, which are based on FY25 financial and actuarial assumptions ^{p. 14}.

Caption: Earnings by segment for 1Q26 with various changes. ^{p. 14}

| EUR m | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | 1Q26 | Change | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- ---|------| | France iii,iv | 3,348 | +11% | 96 | +2% | 112 | +8% | 3.3% | -0.1 pt | 1,815 | +16% | — | — | 46 | +5% | 2.5% | -0.3 pt | 5,162 | +12% | 96 | +2% | 158 | +7% | 3.1% | -0.1 pt | | | Europe iv | 3,287 | +8% | 187 | -1% | 156 | -5% | 4.8% | -0.7 pt | 1,707 | +4% | 89 | +17% | 77 | +15% | 4.5% | +0.4 pt | 4,994 | +7% | 275 | +4% | 233 | 0% | 4.7% | -0.3 pt | | | Asia, Africa & EME-LATAM | 3,129 | +11% | 178 | +13% | 178 | +7% | 5.7% | -0.2 pt | 407 | -26% | 46 | -22% | 37 | -32% | 9.1% | -0.8 pt | 3,536 | +5% | 224 | +4% | 215 | -2% | 6.1% | -0.5 pt | | | Transversal iii | 67 | +7% | 5 | +7% | 3 | +7% | 5.2% | 0.0 pt | — | — | — | — | — | — | — | — | 67 | +7% | 5 | +7% | 3 | +7% | 5.2% | 0.0 pt | | | Total | 9,831 | +10% | 466 | +5% | 450 | +3% | 4.6% | -0.3 pt | 3,929 | +4% | 135 | -1% | 160 | -4% | 4.1% | -0.4 pt | 13,760 | +8% | 601 | +4% | 609 | +1% | 4.4% | -0.3 pt | |

New Business Value (NBV) breakdown for Life and Health. ^{p. 14}
EUR m	Life	Health	Total
NB CSM (pre-tax)	466	135	601
Other NBV(pre-tax)	125	73	198
Tax	-142	-48	-190
NBV	450	160	609

This section includes Health business predominantly written in Life entities ^{p. 14}.
Changes are calculated on a comparable basis (constant forex, scope, and methodology) ^{p. 14}.
This section is titled "APPENDIX 9: OTHER APPENDIX 7: LIFE & HEALTH -NET FLOWS" ^{p. 15}.

Net flows by business line

Net flows by business line for 1Q25 and 1Q26. ^{p. 15}
EUR bn	1Q25	1Q26
Health i	+0.8	+1.0
Protection	+1.8	+1.8
G/A Savings	-0.7	-0.8

Capital light and traditional G/A net flows. ^{p. 15}
o/w capital light	+0.6	+0.7

Unit-Linked and Total Life & Health net flows. ^{p. 15}
Unit-Linked	+0.5	+0.7
Total Life & Health i net flows	+2.5	+2.7

Health business written predominantly in Life entities is included ^{p. 15}.
Capital light G/A encompasses all products without guarantees, with guarantees only at maturity, or with guarantees equal to or lower than 0% ^{p. 15}.
Investment contracts with no discretionary participation features ('DPF') are included ^{p. 15}.
AXA announced the execution of a share repurchase agreement for its share buyback program of up to EUR 1.25bn on February 27, 2026 ^{p. 16}.
Upcoming main investor events include:
- HY26 Earnings Release on July 31, 2026 ^{p. 16}.
- AXA Investor Day on September 15, 2026 ^{p. 16}.
- AXA Investor roundtable on the strategy for AXA key markets on September 21, 2026 ^{p. 16}.
- 9M26 Activity Indicators on October 29, 2026 ^{p. 16}.